{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:08:29Z","timestamp":1761505709415,"version":"build-2065373602"},"reference-count":54,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.cllc.2014.10.006","type":"journal-article","created":{"date-parts":[[2014,10,31]],"date-time":"2014-10-31T16:08:41Z","timestamp":1414771721000},"page":"221-227","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Response to Cytotoxic Chemotherapy in Patients Previously Treated With Palliative-Intent Chemotherapy for Advanced Thymic Carcinoma"],"prefix":"10.1016","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5743-0149","authenticated-orcid":false,"given":"Yusuke","family":"Okuma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukio","family":"Hosomi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiharu","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuru","family":"Okamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsunekazu","family":"Hishima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2014.10.006_bib1","unstructured":"Rare Cancers Europe. Available at: http:\/\/www.rarecancerseurope.org\/. Accessed: November 16, 2014."},{"key":"10.1016\/j.cllc.2014.10.006_bib2","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/ijc.11099","article-title":"Malignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies","volume":"105","author":"Engels","year":"2003","journal-title":"Int J Cancer"},{"key":"10.1016\/j.cllc.2014.10.006_bib3","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ejca.2007.11.004","article-title":"Thymic epithelial tumours: a population-based study of the incidence, diagnostic procedures and therapy","volume":"44","author":"de Jong","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cllc.2014.10.006_bib4","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/00000478-199003000-00010","article-title":"Histology of the normal thymus","volume":"14","author":"Suster","year":"1990","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.cllc.2014.10.006_bib5","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1046\/j.1365-2559.2000.00846.x","article-title":"Cytokeratin profiles of the thymus and thymomas: histogenetic correlations and proposal for a histological classification of thymomas","volume":"36","author":"Kuo","year":"2000","journal-title":"Histopathology"},{"key":"10.1016\/j.cllc.2014.10.006_bib6","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1200\/JCO.2010.32.9607","article-title":"Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma","volume":"29","author":"Lemma","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2014.10.006_bib7","doi-asserted-by":"crossref","first-page":"Abstr 7529","DOI":"10.1200\/jco.2013.31.15_suppl.7529","article-title":"A multicenter prospective study of carboplatin and paclitaxel for advanced thymic carcinoma: West Japan Oncology Group 4207L","volume":"31l","author":"Takeda","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2014.10.006_bib8","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.1997.15.9.3093","article-title":"Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trial","volume":"15","author":"Loehrer","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2014.10.006_bib9","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1586\/era.12.29","article-title":"Chemotherapy and targeted agents for thymic malignancies","volume":"12","author":"Girard","year":"2012","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.cllc.2014.10.006_bib10","doi-asserted-by":"crossref","first-page":"562","DOI":"10.6004\/jnccn.2013.0072","article-title":"Thymomas and thymic carcinomas: clinical practice guidelines in oncology","volume":"11","author":"Ettinger","year":"2013","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.cllc.2014.10.006_bib11","doi-asserted-by":"crossref","first-page":"4820","DOI":"10.1200\/JCO.2011.36.0487","article-title":"Thymic malignancies: from clinical management to targeted therapies","volume":"29","author":"Kelly","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2014.10.006_bib12","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1056\/NEJM200406173502523","article-title":"Thymic carcinoma with overexpression of mutated KIT and the response to imatinib","volume":"350","author":"Strobel","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cllc.2014.10.006_bib13","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/sj.bjc.6605740","article-title":"Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience","volume":"103","author":"Strobel","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cllc.2014.10.006_bib14","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.thorsurg.2010.08.011","article-title":"The role of radiotherapy in the management of thymic tumors","volume":"21","author":"Girard","year":"2011","journal-title":"Thorac Surg Clin"},{"key":"10.1016\/j.cllc.2014.10.006_bib15","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/JTO.0b013e3181a52e25","article-title":"Long lasting response to the multikinase inhibitor bay 43-9006 (Sorafenib) in a heavily pretreated metastatic thymic carcinoma","volume":"4","author":"Bisagni","year":"2009","journal-title":"J\u00a0Thorac Oncol"},{"year":"2004","series-title":"World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of the Lung, Pleura, Thymus and Heart","author":"Travis","key":"10.1016\/j.cllc.2014.10.006_bib16"},{"key":"10.1016\/j.cllc.2014.10.006_bib17","doi-asserted-by":"crossref","first-page":"S304","DOI":"10.1097\/JTO.0b013e3181f20c05","article-title":"Staging system of thymoma","volume":"5","author":"Masaoka","year":"2010","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2014.10.006_bib18","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1097\/JTO.0b013e3181f13682","article-title":"Standard outcome measures for thymic malignancies","volume":"5","author":"Huang","year":"2010","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2014.10.006_bib19","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1002\/1097-0142(19910215)67:4<1025::AID-CNCR2820670427>3.0.CO;2-F","article-title":"Thymic carcinoma. A clinicopathologic study of 60 cases","volume":"67","author":"Suster","year":"1991","journal-title":"Cancer"},{"key":"10.1016\/j.cllc.2014.10.006_bib20","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.lungcan.2012.12.012","article-title":"Clinical outcomes with chemotherapy for advanced thymic carcinoma","volume":"80","author":"Okuma","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2014.10.006_bib21","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/00000421-200206000-00012","article-title":"Chemotherapy for advanced thymic carcinoma: clinical response to cisplatin, doxorubicin, vincristine, and cyclophosphamide (ADOC chemotherapy)","volume":"25","author":"Koizumi","year":"2002","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.cllc.2014.10.006_bib22","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1200\/JCO.1994.12.6.1164","article-title":"Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group","volume":"12","author":"Loehrer","year":"1994","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2014.10.006_bib23","doi-asserted-by":"crossref","first-page":"S357","DOI":"10.1097\/JTO.0b013e3181f21129","article-title":"The role of chemotherapy in advanced thymoma","volume":"5","author":"Schmitt","year":"2010","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2014.10.006_bib24","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1097\/JTO.0b013e31822e71c0","article-title":"Combination chemotherapy with doxorubicin, vincristine, cyclophosphamide, and platinum compounds for advanced thymic carcinoma","volume":"6","author":"Agatsuma","year":"2011","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2014.10.006_bib25","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.lungcan.2009.03.031","article-title":"Efficacy of chemotherapy with carboplatin and paclitaxel for unresectable thymic carcinoma","volume":"67","author":"Igawa","year":"2010","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2014.10.006_bib26","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.lungcan.2011.05.013","article-title":"Cisplatin and irinotecan combination chemotherapy for advanced thymic carcinoma: evaluation of efficacy and toxicity","volume":"74","author":"Okuma","year":"2011","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2014.10.006_bib27","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1200\/JCO.1996.14.3.814","article-title":"Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group","volume":"14","author":"Giaccone","year":"1996","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2014.10.006_bib28","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1200\/JCO.2003.09.130","article-title":"Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597","volume":"21","author":"Masters","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2014.10.006_bib29","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1093\/jjco\/hyf059","article-title":"A\u00a0case of recurrent metastatic thymoma showing a marked response to paclitaxel monotherapy","volume":"32","author":"Umemura","year":"2002","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.cllc.2014.10.006_bib30","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1200\/JCO.1999.17.9.2737","article-title":"Treatment of invasive thymoma with single-agent ifosfamide","volume":"17","author":"Highley","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2014.10.006_bib31","first-page":"7079","article-title":"A\u00a0phase II trial of pemetrexed in patients with recurrent thymoma or thymic carcinoma (abstract)","volume":"24","author":"Loehrer","year":"2006","journal-title":"ASCO Meeting Abstracts"},{"key":"10.1016\/j.cllc.2014.10.006_bib32","first-page":"1331","article-title":"Thymic carcinoma with autoimmune syndrome: successful treatment with weekly infusional high-dose 5-fluorouracil and leucovorin","volume":"17","author":"Hsu","year":"1997","journal-title":"Anticancer Res"},{"key":"10.1016\/j.cllc.2014.10.006_bib33","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/annonc\/mdh216","article-title":"Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system","volume":"15","author":"Oberg","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2014.10.006_bib34","doi-asserted-by":"crossref","first-page":"S1749","DOI":"10.1097\/JTO.0b013e31821ea5f7","article-title":"Chemotherapy definitions and policies for thymic malignancies","volume":"6","author":"Girard","year":"2011","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2014.10.006_bib35","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1093\/jjco\/hyt106","article-title":"Amrubicin as second-line and beyond treatment for platinum-refractory advanced thymic carcinoma","volume":"43","author":"Hirai","year":"2013","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.cllc.2014.10.006_bib36","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1159\/000082626","article-title":"Efficacy of docetaxel as a second-line chemotherapy for thymic carcinoma","volume":"50","author":"Oguri","year":"2004","journal-title":"Chemotherapy"},{"key":"10.1016\/j.cllc.2014.10.006_bib37","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.lungcan.2010.09.004","article-title":"S-1 is an active anticancer agent for advanced thymic carcinoma","volume":"70","author":"Okuma","year":"2010","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2014.10.006_bib38","first-page":"4851","article-title":"Salvage chemotherapy with carboplatin and paclitaxel for cisplatin-resistant thymic carcinoma\u2013three cases","volume":"26","author":"Komatsu","year":"2006","journal-title":"Anticancer Res"},{"key":"10.1016\/j.cllc.2014.10.006_bib39","doi-asserted-by":"crossref","first-page":"6790","DOI":"10.1158\/1078-0432.CCR-09-0644","article-title":"Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas","volume":"15","author":"Girard","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2014.10.006_bib40","doi-asserted-by":"crossref","first-page":"S291","DOI":"10.1097\/JTO.0b013e3181f209b9","article-title":"Thymic tumors: relevant molecular data in the clinic","volume":"5","author":"Girard","year":"2010","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2014.10.006_bib41","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1097\/JTO.0b013e3181e392a8","article-title":"Insulin-like growth factor-1 receptor expression in thymic malignancies","volume":"5","author":"Girard","year":"2010","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2014.10.006_bib42","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1200\/JCO.2010.32.4467","article-title":"Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors","volume":"29","author":"Giaccone","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2014.10.006_bib43","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S1470-2045(13)70596-5","article-title":"Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial","volume":"15","author":"Rajan","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2014.10.006_bib44","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s12032-008-9100-0","article-title":"Response to sorafenib in cisplatin-resistant thymic carcinoma: a case report","volume":"26","author":"Li","year":"2009","journal-title":"Med Oncol"},{"key":"10.1016\/j.cllc.2014.10.006_bib45","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1093\/annonc\/mdr626","article-title":"Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors","volume":"23","author":"Schirosi","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2014.10.006_bib46","doi-asserted-by":"crossref","unstructured":"Thomas A, Rajan A, Berman AW, et\u00a0al. Phase II trial of sunitinib in patients with thymic epithelial tumors (TET). ASCO Meeting Abstracts 2014; 32:7525.","DOI":"10.1200\/jco.2014.32.15_suppl.7525"},{"key":"10.1016\/j.cllc.2014.10.006_bib47","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/(SICI)1097-0215(19971127)73:5<639::AID-IJC5>3.0.CO;2-Y","article-title":"p16INK4, pRB, p53 and cyclin D1 expression and hypermethylation of CDKN2 gene in thymoma and thymic carcinoma","volume":"73","author":"Hirabayashi","year":"1997","journal-title":"Int J Cancer"},{"key":"10.1016\/j.cllc.2014.10.006_bib48","doi-asserted-by":"crossref","unstructured":"Besse B, Garassino MC, Rajan A, et\u00a0al. A phase II study of milciclib (PHA-848125AC) in patients (pts) with thymic carcinoma (TC). ASCO Meeting Abstracts 2014; 32:7526.","DOI":"10.1200\/jco.2014.32.15_suppl.7526"},{"key":"10.1016\/j.cllc.2014.10.006_bib49","doi-asserted-by":"crossref","first-page":"111","DOI":"10.5306\/wjco.v3.i7.111","article-title":"Everolimus plus long-acting somatostatin analogs in thymic epithelial malignancies","volume":"3","author":"Palmieri","year":"2012","journal-title":"World J Clin Oncol"},{"key":"10.1016\/j.cllc.2014.10.006_bib50","doi-asserted-by":"crossref","unstructured":"Zucali PA, De Pas TM, Palmieri G, et\u00a0al. Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy. ASCO Meeting Abstracts 2014; 32:7527.","DOI":"10.1200\/jco.2014.32.15_suppl.7527"},{"key":"10.1016\/j.cllc.2014.10.006_bib51","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1097\/SLA.0b013e3181dd4ec4","article-title":"Thymic neuroendocrine tumors: a SEER database analysis of 160 patients","volume":"251","author":"Gaur","year":"2010","journal-title":"Ann Surg"},{"key":"10.1016\/j.cllc.2014.10.006_bib52","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.lungcan.2012.12.001","article-title":"Treatment, prognostic markers and survival in thymic neuroendocrine tumours. A study from a single tertiary referral centre","volume":"79","author":"Crona","year":"2013","journal-title":"Lung Cancer"},{"issue":"suppl 7","key":"10.1016\/j.cllc.2014.10.006_bib53","doi-asserted-by":"crossref","first-page":"vii120","DOI":"10.1093\/annonc\/mds267","article-title":"Neuroendocrine bronchial and thymic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"23","author":"Oberg","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2014.10.006_bib54","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1093\/annonc\/mdp483","article-title":"Preliminary results of phase II study of capecitabine and gemcitabine (CAP-GEM) in patients with metastatic pretreated thymic epithelial tumors (TETs)","volume":"21","author":"Palmieri","year":"2010","journal-title":"Ann Oncol"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730414002356?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730414002356?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:04:31Z","timestamp":1761505471000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730414002356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S1525730414002356"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2014.10.006","relation":{},"ISSN":["1525-7304"],"issn-type":[{"type":"print","value":"1525-7304"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Response to Cytotoxic Chemotherapy in Patients Previously Treated With Palliative-Intent Chemotherapy for Advanced Thymic Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2014.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}